News | September 24, 2007

FDA Clears Memo 3D Annuloplasty Ring

September 25, 2007 - The Sorin Group, a European cardiovascular company, announced today that it has received FDA clearance for marketing its MEMO 3D Semirigid Annuloplasty Ring in the U.S., targeting patients receiving mitral valve repair as therapy for mitral valve disease.

Annuloplasty rings are indicated for repair of the mitral valve and are designed to remodel the anatomical shape of the mitral annulus, preventing further dilatation and minimizing the risk of late repair failures.

Its core structure reportedly enables the MEMO 3D ring to restore the natural mitral annulus’ three-dimensional motility during the cardiac cycle.

The MEMO 3D Semirigid Annuloplasty Ring has a cell-structure design, capable of mimicking the physiological three-dimensional motility of the native mitral annulus and accommodating the anatomical saddle shape. The shape memory and super-elastic alloy core is aimed at restoring the native shape and function. Carbofilm coating reportedly enhances hemo-compatibility. The suture placement guides, a low profile holder and a special configuration of the silicon filler, is designed for ease of implant.

The MEMO 3D annuloplasty ring has already been introduced in several European countries. CarboMedics Inc., Sorin Group’s U.S. subsidiary, will distribute MEMO 3D in the U.S.

For more information: www.sorin.com

Related Content

HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Sponsored Content | Videos | Heart Valve Technology| January 03, 2017
This video, provided by Valtech, demonstrates the Cardioband transcatheter mitral annuloplasty system.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings| February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings| September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Valtech, cardioband, transcatheter mitral annuloplasty

Valtech's Cardioband transcatheter mitral annuloplasty system in development. It is uses a series of corkscrew anchors, similar to those used on EP implantable device leads, to install the annuloplasty ring to reshape the valve for improved leaflet coaptation.

Feature | Structural Heart| September 02, 2015
September 2, 2015 — HeartWare International Inc.
Mitralign, Percutaneous Tricuspid Valve Annuloplasty System

Mitralign's Percutaneous Tricuspid Valve Annuloplasty System uses catheter delivered pledgeted sutures that can be cinched together to change the valve annulus geometry to help eliminate valvular regurgitation. 

News | Heart Valve Technology| August 31, 2015
August 31, 2015 — Mitralign Inc. said the U.S.
Mitralign, six-month data, EuroPCR 2015, MPAS

Image courtesy of Mitralign.

Feature | June 01, 2015
Mitralign shared six-month data on its Mitralign Percutaneous Annuloplasty System (MPAS) for treatment of functional...
Overlay Init